Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 3/20 | 0.45 |
| ▸ | CCR4 | P51679 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991310 | 1.00 | EDNRA (0.45) | EDNRACCR4DYRK1ANR4A2GPR84 | |
| SCHEMBL20339142 | 0.85 | POLB (0.50) | EDNRAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL23620235 | 0.84 | EDNRA (0.45) | EDNRACCR4DYRK1AMEN1KMT2A | |
| SCHEMBL30286552 | 0.81 | EDNRA (0.45) | EDNRADYRK1ANR4A2GPR84POLB | |
| SCHEMBL20355221 | 0.81 | KMT2A (0.48) | EDNRAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL20354701 | 0.81 | SLC22A12 (0.47) | HTT | |
| SCHEMBL20355218 | 0.81 | EDNRA (0.45) | EDNRADYRK1ANR4A2GPR84POLB | |
| SCHEMBL29560013 | 0.81 | SLC22A12 (0.47) | HTT | |
| SCHEMBL20339162 | 0.79 | NR4A2 (0.36) | EDNRADYRK1ANR4A2GPR84POLB | |
| SCHEMBL30286553 | 0.79 | NR4A2 (0.36) | EDNRADYRK1ANR4A2GPR84POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | UCB PHARMA GMBH (DE) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206749-A1 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | GPR17, GPR18, GPR119 | EDNRA 183/4885CCR4 3113/4885DYRK1A 3097/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | EDNRA 183/4885CCR4 3113/4885DYRK1A 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.